Treatment of lymphoproliferative disease with rituximab

被引：8

作者：

Niedermeyer, J ^{[1
]}

Hoffmeyer, F

Hertenstein, B

Hoeper, MM

Fabel, H

机构：

[1] Univ Med Sch Hannover, Dept Resp Med, D-30625 Hannover, Germany

[2] Univ Med Sch Hannover, Dept Haematol, D-30625 Hannover, Germany

[3] Univ Med Sch Hannover, Dept Oncol, D-30625 Hannover, Germany

来源：

LANCET | 2000年 / 355卷 / 9202期

关键词：

D O I：

10.1016/S0140-6736(00)82057-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：499 / 499

页数：1

共 4 条

[1]

ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877

[2] Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation [J].

Cook, RC ;

Connors, JM ;

Gascoyne, RD ;

Fradet, G ;

Levy, RD .

LANCET, 1999, 354 (9191) :1698-1699

[3] NON-HODGKIN-LYMPHOMA IN HEART/LUNG TRANSPLANT RECIPIENTS [J].

EGAN, J ;

STEWART, J ;

YONAN, N ;

ARRAND, J ;

WOODCOCK, A .

LANCET, 1994, 343 (8895) :481-481

[4] Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation [J].

Montone, KT ;

Litzky, LA ;

Wurster, A ;

Kaiser, L ;

Bavaria, J ;

Kotloff, R ;

Palevsky, H ;

Pietra, GG ;

Tomaszewski, JE .

SURGERY, 1996, 119 (05) :544-551

← 1 →